Global Blood Therapeutics Inc(GBT) Finding the best opportunities to buy and sell stocks daily.

Sector:

Healthcare

Description:

Global Blood Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, Oxbryta (voxelotor) tablets, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating Oxbryta that has completed Phase III clinical trial in adult and adolescent patients with SCD. It is also evaluating the safety and pharmacokinetics of single and multiple doses of Oxbryta in a Phase IIa clinical trial of adolescent and pediatric patients with SCD. The company has a license and collaboration agreement with Syros Pharmaceuticals, Inc. to discover, develop, and commercialize therapies for SCD) and beta thalassemia. Global Blood Therapeutics, Inc. was founded in 2011 and is headquartered in South San Francisco, California.

Current Price

$38.23

RSI

38.397

Beta:

1.079977

February 24, 2021
232.8M
-49.6M

1858.966 %
235.610 %
35.602 %
2.354 %

$123,803,000
$2,108,000
$0
$0
$0
$0
5773.008 %
100.000 %
%
%
0.000 %

$-247,553,000
$-266,766,000
$-174,193,000
$-117,024,000
$-82,468,000
$-46,360,000
7.761 %
-34.702 %
-32.819 %
-29.529 %
-43.784 %

News

Press Releases

Notable Dates

All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.